Methyl hydrazinecarbimidothioate hydroiodide
CAS: 35600-34-1
Ref. 3D-FM133227
| 1g | Ausgelaufen | ||
| 2g | Ausgelaufen | ||
| 5g | Ausgelaufen | ||
| 10g | Ausgelaufen | ||
| 25g | Ausgelaufen |
Produktinformation
Name:
Methyl hydrazinecarbimidothioate hydroiodide
Synonyme:
- Hydrazinecarboximidothioic acid methyl ester hydroiodide
- Carbamohydrazonothioic Acid, Methyl Ester
- Methyl carbamohydrazonothioate
Beschreibung:
Methyl hydrazinecarbimidothioate hydroiodide (MHCDI) is an anti-cancer drug that belongs to the group of alkylating agents. It is a prodrug that must be activated by intramolecular hydrogen chloride to form methyl hydrazine, which reacts with the DNA nucleotide bases. MHCDI is used in clinical studies for the treatment of pancreatic cancer, colorectal cancer, and other cancers. MHCDI is administered intravenously, orally, or intraperitoneally. MHCDI binds to nitrogen atoms in the vasoactive intestinal peptide and reacts with hydrochloric acid to form a pyrazole ring. The reaction products are then excreted from the body.
Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:
Chemische Eigenschaften
Molekulargewicht:
233.08 g/mol
Formel:
C2H8IN3S
Reinheit:
Min. 95%
Farbe/Form:
White Powder
MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:
